Trials / Terminated
TerminatedNCT00383214
Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)
A Phase III, Randomized, Double Blind, Placebo Controlled, Multi-Center Study of Epratuzumab in Patients With Active Systemic Lupus Erythematosus.
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of Epratuzumab with standard treatments for patients with SLE.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epratuzumab | 360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion |
| OTHER | Placebo | Intravenous |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2007-03-01
- Completion
- 2007-03-01
- First posted
- 2006-10-03
- Last updated
- 2012-06-07
Locations
60 sites across 11 countries: United States, Belgium, Brazil, Canada, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00383214. Inclusion in this directory is not an endorsement.